mailitics

Category: The Readout LOUD

  • Breaching the IBD efficacy ceiling, and sham surgeries

    Breaching the IBD efficacy ceiling, and sham surgeries Will drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease treatments? We discuss all that on this week’s episode of “The Readout LOUD.” Read the rest… Allison DeAngelis, Adam Feuerstein,…

  • Listen: FDA turmoil, election intrigue, AI, and more

    Listen: FDA turmoil, election intrigue, AI, and more On “The Readout LOUD” this week: Adam Feuerstein, solo. His usual co-hosts Allison DeAngelis and Elaine Chen took some time off, so Adam manned the podcast mic himself.  Adam thought, quite understandably, that our cherished listeners wouldn’t want to hear him drone on for 30 minutes, so…

  • Hims’ Super Bowl fallout, and the FDA reverses course

    Hims’ Super Bowl fallout, and the FDA reverses course Was Hims’ Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what’s happening behind-the-scenes with Moderna and the Food and Drug Administration? We discuss all that on this week’s episode of “The Readout LOUD.” STAT’s Katie Palmer joins…

  • Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s

    Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed…

  • The high stakes for Huntington’s patients

    The high stakes for Huntington’s patients Biotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington’s disease, and the outcome could be potentially devastating for patients. That’s what patient advocate Lauren Holder says on the latest episode of “The Readout LOUD,”…

  • A measles outbreak and hospitals’ financial troubles

    A measles outbreak and hospitals’ financial troubles Why is the U.S. at risk of losing its measles elimination status? How are health officials reacting to the measles outbreak? And what did top Centers for Medicare and Medicaid Services official Mehmet Oz tell hospital executives at a fancy yacht party in San Francisco? We discuss all…

  • Live from JPM 2026, a sit-down with Novo Nordisk’s CEO and VC Bob Nelsen

    Live from JPM 2026, a sit-down with Novo Nordisk’s CEO and VC Bob Nelsen How did an office clerk become CEO of a major pharmaceutical company? What’s “Project Prometheus”? And what’s next in drug R&D? Allison, Adam, and Elaine are asking those questions live from the J.P. Morgan Healthcare Conference in San Francisco. Read the…

  • JPM to bring more deals and happy CEOs

    JPM to bring more deals and happy CEOs What news happened over the holidays? Why will pharma CEOs be greeted warmly in San Francisco next week? And who will buy Revolution Medicines? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. We bring on former co-host…

  • Biotech’s year in review

    Biotech’s year in review Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and more on this week’s episode of “The Readout LOUD,” the last episode of the year. We bring on Bruce…

  • The future of American science and a dispatch from ASH

    The future of American science and a dispatch from ASH How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exactly, is the Trump administration’s plan for reforming the National Institutes of Health? We discuss…

  • A new top drug regulator and the future of psychedelics

    A new top drug regulator and the future of psychedelics On this week’s episode of “The Readout Loud”: a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news.  The turmoil at the Food and Drug…

  • How Mark Cuban plans to ‘f— up’ health care

    How Mark Cuban plans to ‘f— up’ health care How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible program ever”? And what are his thoughts on sports betting? We discuss all that…

  • Merck’s heart disease win and the FDA’s new drug regulator

    Merck’s heart disease win and the FDA’s new drug regulator What does Rick Pazdur’s new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices? Dean Li, the head of R&D at Merck, joins us to discuss…

  • Melodrama at the FDA and the Pfizer-Novo bidding war

    Melodrama at the FDA and the Pfizer-Novo bidding war On this week’s episode of “The Readout LOUD”: “Mean Girls” melodrama at the top of the FDA and the latest on the Pfizer-Novo Nordisk bidding war for Metsera.   On a jam-packed show, your co-hosts, minus the vacationing Allison DeAngelis, chat with STAT’s D.C. correspondent Lizzy Lawrence…

  • BridgeBio’s great week and Moderna’s unraveling

    BridgeBio’s great week and Moderna’s unraveling Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to…

  • Startups push the FDA and biotech booms in North Carolina

    Startups push the FDA and biotech booms in North Carolina Can Trump take credit for North Carolina’s booming biopharma industry? Which drugs could get a shortcut to the market? And who wore a tuxedo to the STAT Summit? We discuss all that and more in the latest episode of “The Readout LOUD.” Read the rest……

  • Party in biotech land and AstraZeneca’s miscalculation

    Party in biotech land and AstraZeneca’s miscalculation Where did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on Mizuho health care…

  • A pharma C-suite shakeup and Trump’s deal with Pfizer

    A pharma C-suite shakeup and Trump’s deal with Pfizer How will we look back on Emma Walmsley’s tenure as GSK’s CEO? Why did one of the FDA’s top drug officials call out an obscure lupus drug on LinkedIn? And will we ever stop talking about the pharma patent cliff? We discuss all that and more…

  • A gene therapy success in Huntington’s and Trump’s autism announcement

    A gene therapy success in Huntington’s and Trump’s autism announcement Why were doctors and investors so excited about trial results of UniQure’s gene therapy for Huntington’s disease? Are autism rates actually rising? And what does the research tell us about Tylenol and autism? We discuss all that on this week’s episode of the “The Readout…

  • Pharma sours on the U.K., plus biotech M&A’s quiet roll

    Pharma sours on the U.K., plus biotech M&A’s quiet roll Are pharmaceutical companies pulling their money out of the United Kingdom because of Trump? How is biotech M&A pacing this year? And what will vaccine advisors discuss at their closely watched meeting this week? We discuss all that and more on this week’s episode of…

  • Trump, Chinese biotech, and an industry career reshaped by illness

    Trump, Chinese biotech, and an industry career reshaped by illness On this week’s episode of “The Readout LOUD”: a drug-industry career reshaped by illness, and the potential for political blowback against Chinese biotech. Listeners of this podcast probably know pharma consultant Mike Rea for his annual ranking of drug company R&D productivity. But this week,…

  • New stakes in the vaccine dispute and a boost for biotech

    New stakes in the vaccine dispute and a boost for biotech Does President Trump deserve a Nobel Peace Prize for Operation Warp Speed? What will health secretary Robert F. Kennedy Jr. tell Congress about the changes at the Centers for Disease Control and Prevention? And is biotech back? We discuss all that and more on…

  • The ouster of CDC’s director, biotech venture firm rankings

    The ouster of CDC’s director, biotech venture firm rankings What is happening to the leadership of the Centers for Disease Control and Prevention? Which biotech venture capital firm has generated the best returns for investors? And how did cat hair show up inside a major drug manufacturing plant? We discuss all that on this week’s…

  • Viking’s obesity flop, ‘pharma to table’ drug sales

    Viking’s obesity flop, ‘pharma to table’ drug sales On this week’s episode of “The Readout LOUD”: vikings. No, not the seafaring Norse people of the 10th century, or the Minnesota football team. The gang will discuss obesity drug developer Viking Therapeutics and the investor cult that embraces it, both of which performed a painful belly…

  • Vinay Prasad’s return, animal testing alternatives, and mRNA upended

    Vinay Prasad’s return, animal testing alternatives, and mRNA upended Have investors soured on mRNA biotechs? How will Vinay Prasad approach his role at the Food and Drug Administration the second time around? And how do you pronounce “bronchiectasis”? We address all that and more on this week’s episode of “The Readout LOUD.” We discuss the…

  • Closing a zombie biotech, and Lilly’s disappointing obesity readout

    Closing a zombie biotech, and Lilly’s disappointing obesity readout How does a biotech company decide to shut itself down? Why does Eli Lilly have so much riding on its oral obesity candidate? And what’s the outlook for Vertex’s pain franchise? We discuss that and more on this on this week’s episode of “The Readout LOUD,”…

  • What Vinay Prasad’s ouster means for biotech and the FDA

    What Vinay Prasad’s ouster means for biotech and the FDA This week’s show is focused on a single topic — the ouster of Food and Drug Administration official Vinay Prasad from his job running the agency’s biologics division. This surprising development came after a series of controversial decisions he made on Sarepta’s gene therapy for…

  • A mother’s perspective on Sarepta’s gene therapy halt

    A mother’s perspective on Sarepta’s gene therapy halt How are families of patients reacting to the removal of Sarepta’s gene therapy from the market? Why are investors excited about narcolpesy drugs? And why has there been less financing in oncology startups? We chat about all that and more on this on this week’s episode of…

  • Inside an FDA drug rejection, and layoffs at Sarepta

    Inside an FDA drug rejection, and layoffs at Sarepta Just how many employees is Sarepta Therapeutics laying off? And why did the Food and Drug Administration reject Ultragenyx’s rare disease drug over manufacturing qualms? We discuss all that and more on this week’s episode of “The Readout LOUD”. Read the rest… Allison DeAngelis, Adam Feuerstein,…

  • NIH grant cuts, FDA transparency questions, and biotech M&A

    NIH grant cuts, FDA transparency questions, and biotech M&A On this week’s episode of “The Readout LOUD”: a closer look at the NIH’s grant-cutting legal playbook, a not-so-transparent transparency push by the FDA commissioner, and another big biotech acquisition.  Our colleague Anil Oza joins us to unravel a previously unseen memo he obtained from HHS…

  • Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects

    Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the Centers for Disease Control and Prevention stand up to her boss? And can Amgen overcome its obesity drug’s side…

  • FDA’s gene therapy turmoil, and an alternative model for funding research

    FDA’s gene therapy turmoil, and an alternative model for funding research Why did the Food and Drug Administration suddenly oust one of its top gene therapy regulators? Is the agency growing too political? And should private firms fund academic research? We chat about all that and more on this on this week’s episode of “The…

  • The upheaval of CDC’s vaccine panel, and drug pricing confusion

    The upheaval of CDC’s vaccine panel, and drug pricing confusion Why did Robert F. Kennedy Jr. abruptly fire all members of the expert panel that advises the Centers for Disease Control and Prevention on vaccines? Who are the new members that Kennedy named? And what does that all mean for the future of public health?…

  • An AI experiment at the FDA & Novo trailing in the obesity drug race

    An AI experiment at the FDA & Novo trailing in the obesity drug race On this week’s episode of “The Readout LOUD”: The Food and Drug Administration’s AI adventure, a deep look inside Novo Nordisk’s obesity stumble, and finally, another big M&A deal in biotech. The FDA has rolled out an internal AI tool called…

  • Moderna’s vaccine hit, the MAHA report, and an ASCO preview

    Moderna’s vaccine hit, the MAHA report, and an ASCO preview What does the MAHA Commission have planned for the drug industry? Why is Robert F. Kennedy Jr. targeting mRNA vaccines? And what are Adam and Elaine getting up to in Chicago? We discuss all that and more on this week’s episode of “The Readout LOUD,”…

  • Uncertainty in CRISPR world and the start of more M&A

    Uncertainty in CRISPR world and the start of more M&A What was the mood like at a big gene therapy conference last week? Why is Novo Nordisk’s CEO stepping down? And why has Adam been in such a good mood? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s…

  • Trump’s drug-pricing plan and a potential Theranos 2.0

    Trump’s drug-pricing plan and a potential Theranos 2.0 How likely is it for President Trump’s new drug-pricing plan to be implemented? Why have investors seemed unbothered by the proposal? And will we see a return of Elizabeth Holmes’ blood-testing ambitions? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s…

  • A firebrand takes oversight of vaccines, gene therapies

    A firebrand takes oversight of vaccines, gene therapies What does the appointment of Vinay Prasad as the head of biologic drug evaluation mean for biotechs? Is his fiery public persona suited for government service? We discuss these and other burning questions on a new episode of “The Readout LOUD,” STAT’s biotech podcast. Read the rest……

  • Assessing the impact of Trump’s first 100 days on science and health policy

    Assessing the impact of Trump’s first 100 days on science and health policy On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong drug launches, and Eli Lilly’s PBM problem.  The first 100 days of the Trump administration have had a profound impact on…

  • Pharma tariffs, and a ‘sunshine day’ for biotech stocks

    Pharma tariffs, and a ‘sunshine day’ for biotech stocks How did Ireland become a hotspot for pharmaceutical manufacturing? What are the products that will come out of Flagship’s latest startup centered around “preemptive medicine”? And who among the co-hosts is the best singer? We discuss all that and more on this week’s episode of “The…

  • BIO’s John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding

    BIO’s John Crowley on RFK Jr. and tariffs, plus calls for more federal biotech funding Is there more funding coming for the biotech industry? Will the pharmaceutical industry be hit with tariffs? And is it possible to reason with RFK Jr.? We talk about all that and more on this week’s episode of “The Readout…

  • Cuts, ousters and drama at the FDA

    Cuts, ousters and drama at the FDA Turmoil, job cuts and forced ousters of high-ranking officials at federal health agencies. Marty Makary’s rough first week as FDA Commissioner. Biotech stocks tumble even further. President Trump’s “Liberation Day” tariffs roil global markets.  We talk about biotech’s volatile week, plus interview AstraZeneca R&D executive Sharon Barr, on…